QR 110

Drug Profile

QR 110

Alternative Names: QR-110

Latest Information Update: 11 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ProQR Therapeutics
  • Class Eye disorder therapies; Oligonucleotides
  • Mechanism of Action Gene expression stimulants; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Leber congenital amaurosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Leber congenital amaurosis

Most Recent Events

  • 15 Jun 2017 Phase-I/II clinical trials in Leber congenital amaurosis (In children, In adolescents, In adults) in Belgium (Intravitreous) (NCT03140969)
  • 15 Jun 2017 Phase-I/II clinical trials in Leber congenital amaurosis in USA (Intravitreous) (NCT03140969)
  • 31 May 2017 QR 110 receives Fast Track designation for Leber congenital amaurosis [Intravitreous,Injection] in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top